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Viruses mercilessly exploit their host cells to guarantee
their own proliferation and propagation. To achieve this
goal, many viruses suppress the apoptotic program, thereby
avoiding premature death of the host cell. Indeed, apopto-
sis of infected cells may be considered as a pristine defense
against infectious pathogens, as illustrated by a simple
 
Gedankenexperiment
 
: if all host cells died immediately after
infection, then the virus could not replicate. It is only at
late stages of the viral life cycle that some viruses actively
induce apoptosis, either in their host cells or, via a variety
of different strategies, in immunologically relevant cells,
with the specific aim to subvert the host’s innate or cognate
immune response. As viruses have coevoluted with their
host to adapt to particular ecological niches, they have
“learned” to target strategic processes in their host cell’s bi-
ology. One fascinating example is now provided by the
poxvirus that causes myxomatosis, a lethal disease which
has been eradicating entire populations of rabbits. Myxoma
virus codes for a protein designated M11L, which, as
shown in this issue (1), inhibits host cell apoptosis by acting
on the peripheral-type benzodiazepine receptor (PBR).
 
M11L: An Antiapoptotic Virulence Factor Targeted to the Mi-
tochondrial PBR.
 
The 18-kD M11L protein is a major vir-
ulence factor for myxomatosis. In vivo, 
 
M11L
 
 knockout
viruses provoke a greatly reduced mortality and induce
more vigorous, presumably host-protective inflammatory
reactions than pathogenic wild-type strains. In vitro, 
 
M11L
 
knockout viruses cause accelerated apoptosis in infected
rabbit lymphocytes or monocytes, as compared with wild-
type controls (2, 3), suggesting that M11L acts as an inhibi-
tor of apoptosis. Overexpression of M11L suffices to inhibit
 
apoptosis induced via a variety of nonviral inducers suggest-
ing that it acts as general rather than a virus- or signal-spe-
cific apoptosis inhibitor (1).
 
It is important to note that M11L is not the only anti-
apoptotic virulence factor encoded by myxoma virus. Ad-
ditional antiapoptotic proteins include (a) Serp2, a putative
caspase inhibitor, (b) T2, a TNF receptor homologue
 
which neutralizes proapoptotic TNF
 
 
 
, (c) myxoma virus
leukemia-associated protein, which down-regulates Fas/
CD95 and class I molecules, and (d) T7, an interferon 
 
 
 
 re-
ceptor homologue which inhibits proapoptotic interferon
 
 
 
 (4, 5). Myxoma virus relies on a complex strategy to in-
tercept apoptotic and cytotoxic insults to virus-infected
cells, because deletion of one single gene among these
apoptosis inhibitors suffices to attenuate the virus.
The M11L protein targets mitochondria via a 25 amino
acid long COOH-terminal targeting sequence that is simi-
lar to a unique transmembrane consensus sequence present
in antiapoptotic Bcl-2 family members. Deletion of the
COOH-terminal mitochondrial targeting sequence abol-
ishes the antiapoptotic function of M11L (3) suggesting
that M11L indeed acts on mitochondria to suppress apop-
 
tosis. Importantly, M11L homologues are encoded by other
 
pathogenic poxviruses, namely rabbit fibroma virus (Gp011L),
swinepox virus (C10), sheeppox virus (antiapoptotic viru-
lence factor), lumpy skin disease virus (LSDV017), which
infects cattle in Africa, and the virus responsible for Yaba-
like disease (16L). Several among these proteins (e.g.,
Gp011L, C10) share the COOH-terminal mitochondrial
localization motif with M11L, suggesting that M11L con-
stitutes the prototype of a novel class of apoptosis regulators
acting at the mitochondrial level.
Based on cross-linking studies, FRET analyses and func-
tional tests, it appears that the M11L protein physically and
functionally interacts with the PBR, the benzodiazepine
receptor which is confined to mitochondria (1). The func-
tional interaction between M11L and PBR is abolished by
deletion of the COOH terminus, indicating that the mito-
chondrial localization of M11L is required for its action on
PBR (1). As the interaction of M11L with the PBR is
compatible with simultaneous binding of the synthetic
PBR ligand FGIN-1–27 to its receptor (1), the capacity of
M11L to inhibit apoptosis cannot be attributed to a mere
PBR blockade. Thus, M11L acts as a functional (rather
than competitive) PBR modulator. The question that re-
mains to be answered is how does M11L then act?
 
Mitochondrial Regulation of Apoptosis.
 
Beyond their role
as the cell’s power house, mitochondria exert a major func-
tion as suicide organelles (6). In response to multiple differ-
ent apoptosis-inducing stimuli, which may involve signals as
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different as Ca
 
2
 
 
 
, reactive oxygen species, ganglioside GD3,
proapoptotic members of the Bcl-2 family, kinases, or spe-
cific proteases, mitochondrial membrane permeabilization
(MMP) occurs. Antiapoptotic proteins of the Bcl-2 family
have the property to reside in mitochondrial membranes
and to locally inhibit MMP. Massive MMP is incompatible
with further cell survival and thus indicates that the cell has
trespassed the point-of-no-return of the apoptotic program.
Partial permeabilization of the inner mitochondrial mem-
brane leads to an abrupt collapse of the transmembrane po-
tential (
 
  
 
m
 
), a sign of MMP, while complete permeabili-
zation of the outer membrane, linked to remodeling of
mitochondrial ultrastructure, culminates in the release of
potentially toxic intermembrane proteins into the rest of the
cell. Such intermembrane proteins include caspase activators
such as cytochrome c (which together with Apaf-1 and
caspase-9 forms a caspase-3–activatory complex, the apop-
tosome), and Smac/DIABLO (an inhibitor of the caspase-
inhibitory IAP proteins), as well as caspase-independent
death effectors such as apoptosis-inducing factor (AIF) and
endonuclease-G (7). Apparently, M11L does block MMP,
as it prevents both the dissipation of 
 
  
 
m
 
 (1, 3) and the mi-
tochondrial release of cytochrome c (1).
Permeabilized mitochondria also release endozepine
(also called “acyl-CoA-binding protein” or “diazepam
binding inhibitor”), the endogenous ligand of the PBR (8,
9). On theoretical grounds, endozepine released from mi-
tochondria which have undergone MMP may act on the
PBR of yet intact mitochondria and thus participate in a
positive feedback loop which accelerates MMP induction
throughout the cell (8, 9). The finding that M11L acts on
PBR thus suggests that M11L acts on one of the neuralgic
points of apoptotic control. Indeed, M11L prevents the in-
duction of MMP by protoporphyrin IX, an apoptogenic
PBR ligand, in permeabilized cells (1), suggesting a direct
effect on the mitochondrial checkpoint of apoptosis.
Figure 1. Four alternative (and nonexclusive) hypotheses to explain the apoptosis-inhibitory mode of action of M11L. (A) M11L-mediated blockade
of PBR responses to an endogenous proapoptotic ligand. One of the ligands of PBR, endozepine, is known to be released from mitochondria when they
undergo the apoptotic permeabilization reaction. If endozepine binds to PBR of yet intact mitochondria, thereby participating in the permeabilization
reaction, the function neutralization of PBR would have an antiapoptotic effect by blocking an amplification loop. (B) M11L-mediated alterations of
PBR function having indirect effects on mitochondrial metabolism and apoptotic control. PBR is known to participate in the regulation of mitochon-
drial lipid metabolism, porphyrin transport, and redox sensing. Changes in the function of PBR induced by its interaction with M11L thus could indi-
rectly modulate apoptosis. (C) M11L-mediated alterations in the function of pore-forming proteins within the PTPC. In this scenario, PBR would im-
pinge on the conformation of its interacting partners VDAC and ANT, thereby preventing them to convert into nonspecific pores. Hexokinase II (HKII)
and cyclophilin (CypD) may have similar effects. (D) M11L-induced shifts in the interactions among PTPC proteins. Hypothetically, PBR would, via
complexing ANT and VDAC, prevent the pore-forming interaction with other proteins such as Bax. M11L binding would stimulate this function of
PBR. Proapoptotic proteins, protein complexes, or processes are depicted in red and antiapoptotic ones in green. 
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Whether M11L interrupts a hypothetical endozepine-
mediated, PBR-dependent MMP process (Fig. 1 A), re-
mains, however, a subject of speculation, and other possible
modes of action of M11L are conceivable.
 
PBR: A Regulator of Mitochondrial Apoptosis.
 
PBR is a
widely expressed, evolutionarily conserved 18-kD outer
mitochondrial membrane protein. It is likely to possess a
five-transmembrane structure, and it is endowed with sev-
eral functions including cholesterol transport from the
outer to the inner mitochondrial membrane, regulation of
steroidogenesis, porphyrin transport, sensing of reactive ox-
ygen species, and regulation of apoptosis (10). Transfec-
tion-enforced overexpression of PBR attenuates apoptosis
induced by oxygen radicals or ultraviolet light (10). In line
with this predominantly apoptosis-inhibitory function,
PBR overexpression also enhances the antiapoptotic effect
of M11L (1). The benzodiazepine Ro5–5864 and the iso-
quinoline carboxamide PK11195 exhibit nanomolar affin-
ity for the PBR, and are the archetypic pharmacological
tools for detecting and exploring the receptor (Table I).
Saturating (micromolar) doses of PK11195 or Ro5–4864
can sensitize cancer cells to the induction of apoptosis, ei-
ther in vitro or in vivo (11).
In addition to PK11195 and Ro5–5864, several apopto-
sis-inducing or apoptosis-inhibitory compounds act on the
PBR. Thus, the neuroprotective (antiapoptotic) drug rasa-
giline prevents PK11195 binding to the PBR (12). Con-
versely, the platelet-activating factor (PAF), a phospholipid
involved in neuronal excitotoxicity, induces cytochrome c
release from isolated mitochondria in a fashion that is in-
hibited by PK11195 and Ro5–4864 (13). Photosensitizing
porphyrins, as well as their precursors and derivatives, may
also induce mitochondrial membrane permeabilization and
apoptosis through an effect on the PBR (14).
Although these pharmacological data do not elucidate
the mode of action of PBR, they illustrate the importance
of PBR as an endogenous modulator of mitochondrial
apoptosis and as a prospective drug target. How PBR mod-
ulates apoptosis is not clear. PBR could regulate apoptosis
through indirect effects on mitochondrial metabolism (Fig.
1 B), by serving as a receptor for other apoptosis-relevant
proteins (such as endozepine or perhaps PRAX-1, another
 
Table I.
 
Endogenous Apoptosis Regulatory Proteins Acting at the Mitochondrial Level
 
Target protein
Endogenous
modulators
Viral modulators
or analogs
Pharmacological
modulators (examples)
 
PBR
 
Endozepine
Platelet-activating factor
 
M11L (myxoma virus)
 
PK11195, XK469, FGIN-1-27,
4
 
 
 
-chlorodiazepam, Ro5-4864, BBL22,
protoporphyrin IX, 
 
rasagiline
 
?
VDAC
 
NADH
 
HVB-X protein
 
a
 
BH4 domain peptides
Hexokinase II
Bcl-2
 
, Bax
ANT
 
ATP, ADP
 
Vpr (HIV-1) Atractyloside, 
 
bongkrekate
 
,
 
Bcl-2
 
, Bax
 
vMIA (cytomegalovirus)
 
lonidamine, CD437, MT-21
Oxidative stress
 
Cyclophilin D
 
Misfolded proteins? Unknown
 
Cyclosporin A
N-methyl-4-valine-cyclosporin
N-methyl-4-isoleucine-cyclosporin
Bcl-2
 
/Bax BH3-only proteins
 
BORFB2F, BALF1
 
Peptides containing BH3 motifs
Kinases 
 
  
 
phosphatases
 
5-HL.A179L, HVS-Bcl-2
 
HA-14-1, BH3I-1, BH3I-2
Proteases
 
M11
 
Antimycin A
 
Hexokinase II Glucose
 
, Unknown Unknown
Glucose-6-phosphate
Underline, apoptosis inducers; bold, apoptosis inhibitors.
 
a
 
HVB-X has also been described to inhibit apoptosis. 
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PBR-binding protein), or by influencing the overall func-
tion of a complex of proteins interacting with PBR.
 
The Permeability Transition Pore Complex, a PBR-associated
Polyprotein Complex Targeted by Viral Proteins.
 
PBR inter-
acts with several resident mitochondrial proteins, in partic-
ular with the voltage-dependent anion channel (VDAC)
in the outer membrane and the adenine nucleotide trans-
locase (ANT) in the inner membrane, both of which form
the backbone of a polyprotein complex designated as the
permeability transition pore complex (PTPC). The PTPC
involves additional proteins, in particular hexokinase II
(which binds to the cytosolic face of VDAC), the proteins
from the Bcl-2/Bax family (which interact with VDAC
and ANT), and cyclophilin D (which binds to the matrix
side of ANT). Although the exact stoichiometry and mo-
lecular architecture of the PTPC remains elusive, it has
been extensively documented that Bax-like proteins, VDAC,
and ANT can mediate the permeabilization of model
membranes in vitro (6). Thus, PBR could modulate apop-
tosis through direct molecular interactions with pore-
forming PTPC components (Fig. 1 C). Alternatively, PBR
could influence the molecular dynamics of intra-PTPC
protein–protein interactions in an indirect fashion (Fig. 1
D), for instance by removing VDAC or ANT from their
proapoptotic interaction with cyclophilin D or Bax-like
proteins.
Importantly, Bax-like proteins, VDAC, and ANT have
been identified as targets of pathogenic viral proteins (Ta-
ble I). Thus, the genomes of several viruses code for
death-inhibitory Bcl-2 analogs which preferentially local-
ize to mitochondria and may interact with proapoptotic
Bax homologues: Epstein-Barr virus (proteins: BORFB2F
and BALF1), African swine fever virus (protein 5-HL/
A179L), herpesvirus saimiri (HVS-Bcl-2), Kaposi sar-
coma-associated herpes virus 8 (KSBcl-2), bovine herpes-
virus 4 (BHRF-1), and murine gammaherpesvirus-68
(M11; reference 15). The apoptosis-modulatory hepatitis
B virus X protein (HBV-X) interacts with the human
VDAC3 isoform and stimulates local ROS production
(16). The protein vMIA (viral mitochondrial inhibitor of
apoptosis) encoded by cytomegalovirus specifically inter-
acts with ANT. Mutations of vMIA which abolish its mi-
tochondrial localization also curtail its antiapoptotic func-
tion, suggesting that vMIA indeed acts on mitochondria to
inhibit apoptosis (17).
ANT is also one of the targets of Vpr, a small (96 amino
acids) accessory protein of human immunodeficiency virus-1
(HIV-1), which interacts with ANT through an 
 
 
 
-helical
dodecapeptide domain (residues 71–82) and can form a
composite ion channel with ANT (18). Intriguingly, muta-
tions which abolish the apoptogenic Vpr/ANT interaction,
either due to stop codons (19) or due to a selective point
mutation (R77Q; reference 20), can be found among long-
term nonprogressors, correlating with a decrease in apopto-
sis induction by the corresponding HIV-1 isolates (19).
This strongly suggests that Vpr is an important virulence
factor. These examples illustrate that a variety of different
viruses, in addition to M11L, target the PTPC.
 
The PTPC: A Therapeutic Target?
 
Until now the notion
that PBR controls apoptosis has been based on the non-
physiological overexpression of PBR (10) and on the use of
pharmacological PBR ligands (21), which, especially at
high concentrations, may have additional, PBR-unrelated
effects (22). The finding that a pathogenic virus targets
PBR to inhibit apoptosis (1), thus provides an important
confirmation that PBR does participate in the regulation of
cellular demise. This discovery thus relaunches PBR as a
putative drug target for apoptotic regulation. When com-
bined with cytotoxic agents, PBR ligands reportedly have
therapeutic effects in preclinical animal models of tumor
chemotherapy (11, 23). This applies to diazepam, which
cooperates with lonidamine to eradicate human glioblas-
toma (23), and to Ro5–4864 which cooperates with eto-
poside and ifosfamide to inhibit the growth of human small
cell lung cancers xenografted into nude mice (11). Impor-
tantly, it appears that PBR ligation can overcome apoptosis
resistance conferred by Bcl-2 in a number of models and
that PBR is overexpressed in some tumors (1, 11, 21).
PBR-associated proteins within the PTPC may also
serve as targets for the therapeutic manipulation of apopto-
sis (Table I). Thus, several prospective anti-cancer agents
such as lonidamine and MT21 may target ANT (21). Simi-
larly, small molecules binding to the BH3 peptide-binding
groove of antiapoptotic Bcl-2 family proteins promote can-
cer cell apoptosis (24). The pore forming function of
VDAC can be inhibited by a peptide containing residues
4–23 of Bcl-x(L), the so-called BH4 domain, conjugated to
the protein transduction domain of HIV TAT. Such a pep-
tide (TAT-BH4) can reduce infarct size in a model of heart
ischemia (25). Attempts are also on the way to create non-
immunosuppressive ligands of cyclophilin D which inhibit
the PTPC and have cytoprotective effects in vitro (26) and
cardioprotective effects in vivo (27).
Another fascinating possibility that emerges from the
finding that pathogen-encoded proteins act on PTPC con-
cerns the treatment of viral disease. For instance, if M11L
binding to PBR is required for the lethal development of
myxomatosis, then drugs which inhibit this interaction or
neutralize its functional consequences should cure myx-
omatosis. A similar approach may be envisaged for neutral-
izing viral PTPC-targeted proteins relevant for human dis-
eases such as heptatitis B (HBV-X), cytomegalovirus
infection (mVIA), or AIDS (Vpr).
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